Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $48 from $44 and keeps an Outperform rating on the shares post the Q1 report. The firm left the quarter “pleased,” given a Wakix revenue beat and no negative pipeline surprises, with lead asset Wakix “steadily rumbling toward” becoming a $1B product. Miuzho is most focused on Harmony’s pipeline, which features six programs that are expected to be in Phase 3 by the end of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Market Position and Growth Potential Justify Buy Rating
- Sell Rating for Harmony Biosciences Holdings Due to Patent Litigation Risks and Speculative Pipeline
- Harmony Biosciences Reports Strong Q1 2025 Results
- Harmony Biosciences Reports Strong Earnings and Growth
- Positive Outlook for Harmony Biosciences: Strong EPS Performance and Strategic Growth Initiatives Support Buy Rating